Insmed Valuation

Q: What is the Fair Price of INSM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

INSM * (MX$488.51) is trading below our estimate of [[fair value]] (MX$3537.53)

Is INSM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INSM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INSM * (MX$488.51) is trading below our estimate of fair value (MX$3537.53)

Significantly Below Fair Value: INSM * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INSM *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for INSM *. This is calculated by dividing INSM *'s market cap by their current preferred multiple.
What is INSM *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$3.82b

INSM * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.4x
Enterprise Value/EBITDA	-6.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does INSM *'s PS Ratio compare to its peers?

The above table shows the PS ratio for INSM * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.1x
LAB B Genomma Lab Internacional. de	1.3x	6.2%	Mex$21.8b
688278 Xiamen Amoytop Biotech	12.2x	28.0%	CN¥29.1b
VITR Vitrolife	9x	7.9%	SEK 31.8b
688363 Bloomage BioTechnology	5.8x	15.3%	CN¥33.7b
INSM * Insmed	12.5x	34.6%	Mex$3.8b

Price-To-Sales vs Peers: INSM * is expensive based on its Price-To-Sales Ratio (12.5x) compared to the peer average (8.2x).

Price to Earnings Ratio vs Industry

How does INSM *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: INSM * is expensive based on its Price-To-Sales Ratio (12.5x) compared to the Global Biotechs industry average (10.8x).

Price to Sales Ratio vs Fair Ratio

What is INSM *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INSM * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate INSM *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.